Emerging Infectious Diseases, 2022 Ribavirin has been used widely to treat Lassa fever in West Africa since the 1980s. However, few studies have systematically appraised the evidence for its use.
Hung-Yuan Cheng +8 more
doaj +1 more source
IDCases, 2023 Persistent Hepatitis E Virus infection (HEV) is a rare but increasingly recognised condition in immunocompromised individuals. Untreated, this infection can rapidly progress to cirrhosis.
Jennifer Gallacher +4 more
doaj +1 more source
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]
, 2015 One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A. +2 more
core +2 more sources
Virology Journal, 2011 Background Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin).
Saleem Sana +10 more
doaj +1 more source
Enhancement of Crystallization Process of the Organic Pharmaceutical Molecules through High Pressure
Crystals, 2022 The enhancement of the crystallization process through high pressures was studied by using ribavirin (RVB) as a model compound. The effects of high pressure on crystallization thermodynamics, nucleation kinetics, and process yield were evaluated and ...
Yaoguang Feng +5 more
doaj +1 more source
Tracking TCRß sequence clonotype expansions during antiviral therapy using high-throughput sequencing of the hypervariable region [PDF]
, 2016 To maintain a persistent infection viruses such as hepatitis C virus (HCV) employ a range of mechanisms that subvert protective T cell responses. The suppression of antigen-specific T cell responses by HCV hinders efforts to profile T cell responses ...
Arvind H Patel +10 more
core +3 more sources
Case Reports in Dermatology, 2013 The introduction of ribavirin to hepatitis C combination therapy with pegylated interferon (PEG-IFN)-α2a has improved sustained responses, but it has been accompanied by an increased incidence of cutaneous side effects. Most cases of drug eruption caused
Masahisa Shindo, Isamu Terai
doaj +1 more source
Evaluation of Ribavirin–Poloxamer Microparticles for Improved Intranasal Absorption
Pharmaceutics, 2021 Ribavirin is a water-soluble antiviral compound which, owing to its inability to cross the blood–brain barrier, has limited effectiveness in treating viruses affecting the central nervous system.
Dipy M. Vasa +4 more
doaj +1 more source
Clinical-evolutional particularities of the cryoglobulinemic vasculitis in the case of a patient diagnosed with hepatitis C virus in the predialitic phase [PDF]
, 2018 Hepatitis C virus (HCV) represents a fundamental issue for public health, with long term evolution and the gradual appearance of several complications and associated pathologies.
Boldeanu, Lidia +12 more
core +3 more sources
Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment [PDF]
, 2010 Background Early detection of nonresponders to hepatitis C therapy limits unnecessary exposure to treatment and its side-effects. A recent algorithm combining baseline anti-NS4a antibodies and on-treatment quantitative PCR identified nonresponders to a ...
de Knegt, Robert J +8 more
core +1 more source